Drug

LY-2157299 clinical trials

Also written LY2157299 and Galunisertib.

studies test it: 22
open now: 1
in phase 3: 1
first study started: 2011

Keep track of what changes. Save the LY-2157299 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

22 studies that test it; most in 2016 (5)

Studies that test LY-2157299, by start year
Year	Studies
2011	2
2012	2
2013	2
2014	4
2015	2
2016	5
2017	2
2018	1
2022	1
2023	1

By phase

A phase 1/2 study counts in both.

Phase 1: 16
Phase 2: 11
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular: 4
Pancreatic Neoplasms: 2
Peritoneal Neoplasms: 1
Rectal Neoplasms: 1
Prostatic Neoplasms: 1
Glioblastoma: 1
Carcinosarcoma: 1
Carcinoma: 1
Myelodysplastic Syndromes: 1
Neoplasms: 1
Glioma: 1
Neoplasm Metastasis: 1

Who runs them

Industry 14 · Other 8

Eli Lilly and Company (14) · The Netherlands Cancer Institute (2) · Providence Health & Services (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Oklahoma (1) · Vanderbilt-Ingram Cancer Center (1) · Abramson Cancer Center at Penn Medicine (1) · Sun Yat-sen University (1)

Often tested with

Tested in the same studies.

Paclitaxel (2) · Sorafenib (2) · Capecitabine (1) · Lomustine (1) · Carboplatin (1) · Nivolumab (1) · Durvalumab (1) · Gemcitabine (1)

Studies

Open first, then newest update. How each study uses LY-2157299 is read from its arms, and is right about nine times in ten.

Testing it · 22

See all 22 studies that test LY-2157299 →

Given in every arm · 2 — LY-2157299 is usual care beside what is tested